Bischlorethylnitrosurea
Bischlorethylnitrosurea Brand names, Bischlorethylnitrosurea Analogs
Bischlorethylnitrosurea Brand Names Mixture
- No information avaliable
Bischlorethylnitrosurea Chemical_Formula
C5H9Cl2N3O2
Bischlorethylnitrosurea RX_link
http://www.rxlist.com/cgi/generic3/carmustine.htm
Bischlorethylnitrosurea fda sheet
Bischlorethylnitrosurea msds (material safety sheet)
Bischlorethylnitrosurea Synthesis Reference
Johnston TP et al. J Med Chem 122:669-681(1963).
Bischlorethylnitrosurea Molecular Weight
214.049 g/mol
Bischlorethylnitrosurea Melting Point
31 oC
Bischlorethylnitrosurea H2O Solubility
< 0.1 g/100 mL at 18 °C
Bischlorethylnitrosurea State
Solid
Bischlorethylnitrosurea LogP
1.256
Bischlorethylnitrosurea Dosage Forms
Powder for solution; Wafer
Bischlorethylnitrosurea Indication
For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.
Bischlorethylnitrosurea Pharmacology
Carmustine is one of the nitrosoureas indicated as palliative therapy as a single agent or in established combination therapy with other approved chemotherapeutic agents in treatment of brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. Although it is generally agreed that carmustine alkylates DNA and RNA, it is not cross resistant with other alkylators. As with other nitrosoureas, it may also inhibit several key enzymatic processes by carbamoylation of amino acids in proteins.
Bischlorethylnitrosurea Absorption
5 to 28% bioavailability
Bischlorethylnitrosurea side effects and Toxicity
The oral LD50s in rat and mouse are 20 mg/kg and 45 mg/kg, respectively. Side effects include leukopenia, thrombocytopenia, nausea. Toxic effects include pulmonary fibrosis (20-0%) and bone marrow toxicity.
Bischlorethylnitrosurea Patient Information
No information avaliable
Bischlorethylnitrosurea Organisms Affected
Humans and other mammals
